Promontory Therapeutics has treated its first patients in France as part of the ongoing Phase II clinical trial of PT-112 in patients with late-stage metastatic castration-resistant prostate cancer (mCRPC). The Phase II proof-of-concept study has the objective of characterising the benefit-risk ratio and selecting the optimal dose regimen for pivotal development of PT-112, in line […]
